Patent challenge initiated by Arcutis BiotherapeuticsNESS ZIONA, Israel, April 01, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company pioneering treatments ...

The FDA has so far approved one topical PDE-4 inhibitor, crisaborole (Eucrisa) for atopic dermatitis. It’s available as an ointment in a 2% concentration. The ointment not only delivers the ...

The company announced earlier this month that it was preparing to file application for supplemental new drug application for Vtama (pronounced vee-TAM-uh) this quarter. That announcement also included ...

Once-daily crisaborole ointment 2% may be an effective and well-tolerated long-term maintenance therapy for pediatric and adult patients with mild to moderate atopic dermatitis, according to a ...

Crisaborole ointment 2% (EucrisaTM) is a new anti-inflammatory phosphodiesterase 4 (PDE4) inhibitor that is approved in the United States for the topical treatment of mild to moderate atopic ...

ALLEGAN, Mich., Sept. 28, 2021 /PRNewswire/ -- Padagis announced today that Anacor Pharmaceuticals, Inc initiated patent litigation on September 24, 2021 in the U.S. District Court for the district of ...

ALLEGAN, Mich., Sept. 28, 2021 /PRNewswire/ -- Padagis announced today that Anacor Pharmaceuticals, Inc initiated patent litigation on September 24, ...

ALLEGAN, Mich., Sept. 28, 2021 /PRNewswire/ -- Padagis announced today that Anacor Pharmaceuticals, Inc initiated patent litigation on September 24, 2021 in the U.S. District Court for the ...

Jessica Simpson is worrying fans as a summery and picnic-set photo brings her in promo mode for pharmaceuticals giant Pfizer. The 40-year-old actress, singer, and fashion mogul this week updated her ...

Strides Pharma Science on Tuesday said it has received US health regulator's approval for its generic version of triamcinolone acetonide ointment used for treatment of various skin conditions.

Eucrisa (crisaborole) ointment, 2%, is now approved for the treatment of mild to moderate atopic dermatitis in pediatric patients as young as 3 months old. Previously, the topical treatment had only ...